At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years at informed consent
- ✓Capable and willing to provide written informed consent
- ✓Willing to comply with clinical trial instructions including tumor biopsies if required
- ✓Locally advanced or metastatic cancer with prior systemic therapy or no standard treatment available
- ✕Severe hypersensitivity to investigational product or components (NCI CTCAE v5.0 Grade ≥3)
- ✕Primary immunodeficiency state
- ✕Concurrent opportunistic infection
- ✕Systemic immunosuppressive therapy >2 weeks or oral steroids >10 mg/day prednisone within 7 days
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced/Metastatic Malignant Solid Tumors
In Brief
A Phase 1 clinical trial evaluating CRD3874 for Sarcoma and Merkel Cell Carcinoma. Currently recruiting, targeting 81 participants across 7 sites.
Signals
Detailed Summary
This study will test the safety of a study drug called CRD3874-SI. The researchers will test different doses of CRD3874-SI to find the highest dose that causes few or mild side effects in participants. After the researchers find the highest safe dose of CRD3874-SI, they will test that dose in new groups of participants to help them learn more about the side effects of the study drug and find out whether CRD3874-SI is an effective treatment for for patients with advanced or metastatic malignant solid tumors including sarcoma and Merkel Cell Carcinoma. (MCC), Head and neck squamous cell carcinoma (HNSCC), Adenoid cycstic carcinoma (ACC), Uveal Melanoma, Muscosal and Acral melanoma, and Non small cell lung cancer. The researchers will also look at how the body absorbs, distributes, and gets rid of CRD3874-SI, and the how the body and immune system respond to CRD3874-SI.
Study Details
Timeline
Interventions
Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI. Cohort CRD3874-SI Dose level (mg/kg) 1. 0.1 2. 0.3 3. 0.9 4. 1.8 5. 2.7 6. 4.05